Feature | Breast Imaging | March 07, 2018 | By Jeff Zagoudis

Greater Evidence, Payment Expansion Driving Tomosynthesis Adoption

This article originally ran as the Breast Tomosynthesis Systems chart introduction in the March 2018 issue. The chart can be viewed here.

Fujifilm introduced a DBT option to the Aspire Cristalle full-field digital mammography (FFDM) system in 2017 following FDA approval for the upgrade.

Fujifilm introduced a DBT option to the Aspire Cristalle full-field digital mammography (FFDM) system in 2017 following FDA approval for the upgrade.

In the world of breast imaging, digital breast tomosynthesis (DBT) is a relative newcomer, only being adopted into clinical practice in the last 8 years. The benefits of DBT, also known as 3-D mammography, are generally understood — improved cancer detection over traditional 2-D mammography due to the ability to scroll through different slices of the breast to see lesions undetectable in two dimensions. While the evidence for DBT has been mounting, new data reveal the technology has seen explosive growth in the last 18 months.

The U.S. Food and Drug Administration (FDA) tracks statistics on certified mammography facilities and systems across the United States under the directive of the Mammography Quality Standards Act (MQSA), and in June 2016 the FDA began monitoring certification of breast tomosynthesis systems. At that time, out of 8,740 mammography facilities in the U.S., just 2,444 (about 28 percent) had 3-D mammography systems (for a total of 3,362 DBT machines). As of Dec. 1 of last year, however, FDA data showed a total of 5,394 systems in service at 3,866 centers.

“There is still plenty of lingering confusion caused by screening guidelines that were developed with 2-D technology in mind, which is having a negative impact on the adoption of tomosynthesis in some areas,” said Tracy Accardi, global vice president of research and development, breast and skeletal health division at Hologic. Accardi attributed the rapid growth of DBT to expanding clinical evidence, as well as several recent state and national payer updates that she said have brought the total population of women ages 40 to 75 covered for tomosynthesis to 90 percent.

 

Tomo Vendors Remain Limited

Currently, Hologic is one of only four DBT manufacturers in the market, joined by Siemens, Fujifilm and GE Healthcare.

Hologic was the first to bring tomosynthesis to the commercial market when it received FDA approval for the Selenia Dimensions system in 2011. Its newest premium DBT system, 3Dimensions, provides high-quality 3-D images with Clarity HD High-Resolution 3-D imaging to clearly reveal subtle lesions and fine calcifications, regardless of a patient’s breast size or fibroglandular breast density. The 3Dimensions system also features Intelligent 2-D mapping technology that allows radiologists to instantly move from suspicious areas on the 2-D results to the point of interest on the 3-D slice, optimizing workflow. Clarity HD High-Resolution 3-D imaging and Intelligent 2-D technology are both pending FDA approval.

Siemens Healthineers made the most recent introduction to the market, debuting its newest premium digital mammography system, Mammomat Revelation, at the 2017 Radiological Society of North America (RSNA) annual meeting last November in Chicago. The Mammomat Revelation features 50-degree 3-D HD Breast Tomosynthesis, which Siemens says is the widest scan angle in the industry. In addition, the system adds an HD Breast Biopsy feature that allows the acquisition and scanning of biopsy samples at a single station (rather than two separate systems as is custom) in 20 seconds or less, significantly streamlining workflow. Technologists can target a suspicious area in a scan with one click, down to ±1 mm accuracy. The Mammomat Revelation is still pending FDA approval.

Fujifilm introduced a DBT option to the Aspire Cristalle full-field digital mammography (FFDM) system in 2017 following FDA approval for the upgrade. Unlike other mammography systems, the detector on the Aspire Cristalle uses a hexagonal close pattern (HCP) design, which Fujifilm says improves the efficiency of signal capture and results in a higher-quality image. The system also features advanced image processing and image acquisition workflow to optimize patient dose.

GE Healthcare put the emphasis on patient comfort with its latest mammography system release, the Senographe Pristina, which debuted at RSNA 2016 and was cleared by the FDA in September last year. The system takes what is often the most uncomfortable part of the mammography exam for patients — breast compression — and literally puts it in the patient’s hands with the Dueta remote control. The patient can gradually increase compression after initial setup from the technologist until adequate compression is achieved.

Hologic also brought the idea of patient-centered care to the new 3Dimensions system via the SmartCurve breast stabilization system (which is still pending FDA approval). This compression plate features a curved surface that mirrors the shape of a woman’s breast to reduce pinching and allow better distribution of force over the entire breast. 

Related Content

Christopher Comstock, M.D., ECOG-ACRIN Cancer Research Group study published in JAMA builds evidence for use of abbreviated MRI in women with dense breasts

Christopher Comstock, M.D., (Memorial Sloan Kettering Cancer Center) is the lead author of a paper in JAMA that reports that abbreviated breast MRI detected significantly more (almost 2 and a half times as many) breast cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breasts. Photo courtesy of Memorial Sloan Kettering Cancer Center

News | Breast Imaging | February 26, 2020
February 26, 2020 — According to a study
Women 75-plus May Not Benefit from Breast Cancer Screening
News | Mammography | February 25, 2020
February 25, 2020 — According to newly published research in an article titled...
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...